Getinge completed the acquisition of High Purity New England for $290m.

Getinge, a global medical technology company, completed the acquisition of High Purity New England, a provider of single-use solutions for bioprocessing applications, for $290m. "This acquisition is another step in Getinge Life Science strategic journey to further expand our presence in the biopharma segment. High Purity New England has in recent years successfully supplied the industry with dedicated single use assemblies. We are delighted to join forces with HPNE providing our customers with comprehensive and innovative solutions for bioprocessing applications," Eric Honroth, Getinge President Life Science.